The original headline attributed the words “The damage to DNA lasts a lifetime” to Dr. Daniel Landau of The Mesothelioma Center. That attribution has not been independently verified here, and the quotation should not be read as a prognosis for every cancer patient. Some chemotherapy-related genetic changes can persist, but the linked research does not show that every DNA injury lasts for life, that all drugs have identical effects or that every treated person will develop another cancer.
A study of healthy blood after treatment
Published in July 2025, the original Nature Genetics paper studied blood-cell genomes after chemotherapy. It found treatment-associated mutations and altered populations of blood-forming cells, with differences among medicines and cell types. Some patterns resembled changes ordinarily associated with ageing.
Those findings help explain biological consequences of treatment. They do not turn a blood-cell mutation count into a person’s “true age,” and they are not direct measurements of whether chemotherapy shortened or extended that person’s life.
Important research, with limits
The study was small and participants had differing cancer histories and treatment combinations. It cannot provide a precise personal risk estimate for every regimen. The Wellcome Sanger Institute described the work as a starting point for larger studies, including investigation of other normal tissues.
The practical research goal is better cancer treatment with fewer avoidable harms. Where two treatments control a cancer equally well, additional information about long-term toxicity could eventually help guide selection. That does not mean every less-mutagenic option is already an effective substitute for every cancer.
Questions worth taking to an oncology visit
Ask about both the expected cancer benefit and the relevant late effects of the proposed regimen. The aim may be cure, reducing recurrence, controlling disease or easing symptoms. These are different situations, and the acceptable balance of benefit and harm will differ.
After treatment, a survivorship plan should record the drugs and doses received, the follow-up schedule and symptoms that need attention. The National Cancer Institute recommends sharing a treatment summary with other clinicians and discussing new or persistent physical and emotional problems. A new symptom does not automatically mean recurrence, but it should not be dismissed.
Patients should have honest information about delayed harm without being left with the impression that treatment makes recovery futile. Do not stop chemotherapy or replace it with an unproven remedy on the basis of this quotation. Review concerns with the treating team, using evidence about the actual cancer and treatment options.
References
- Mitchell et al., Nature Genetics (2025): The long-term effects of chemotherapy on normal blood cells
- Wellcome Sanger Institute: Genetic damage from some chemotherapies
- National Cancer Institute: Chemotherapy to Treat Cancer
- National Cancer Institute: Follow-Up Medical Care
- National Cancer Institute: Late Effects of Cancer Treatment
